Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anlotinib + benmelstobart
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Anlotinib + benmelstobart is a combination therapy consisting of two agents: - **Anlotinib** is a multi-targeted small molecule tyrosine kinase inhibitor with anti-angiogenic properties. It inhibits several targets involved in tumor angiogenesis and proliferation. - **Benmelstobart (TQB2450)** is a humanized monoclonal antibody that targets programmed death-ligand 1 (PD-L1), functioning as an immune checkpoint inhibitor. This combination has been studied primarily in the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) and advanced renal cell carcinoma. In ES-SCLC, it is typically combined with standard chemotherapy (etoposide plus carboplatin). The regimen has demonstrated significant improvements in progression-free survival and overall survival compared to chemotherapy alone or other immunotherapy regimens. The safety profile is considered tolerable and manageable[1][2][4][6].
- Brand names
- benmelstobart
- Other names
- anlotinib + TQB2450benmelstobart + anlotinib
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR2 (Keratinocyte growth factor receptor)PDGFRA (Platelet-derived growth factor receptor alpha)
Beyond the preview
Go deeper on anlotinib + benmelstobart.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anlotinib + benmelstobart.